Skip to content
Screener

Aclaris Therapeutics ACRS Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue$1.5MMiss by $2.1M
EPS-$0.12Beat by $0.05
Revenue estimate$3.6M
EPS estimate-$0.17

Next report

Nov 5, 2026 (in a month)
Revenue estimate$1.3M
EPS estimate-$0.16

Financials

Q1 2025

Income statement

See full
Revenue$1.5M-39.3%
Gross profit$949.0K-40.3%
Operating income-$18.1M+4.5%
Net income-$15.1M+11.0%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$30.4M-15.3%
Total debt$2.5M-28.5%
Total equity$144.1M+1.4%
Total assets$198.1M+13.8%

Cash flow

See full
Operating cash flow-$13.1M+37.3%
CapEx$43.0K-68.1%
Free cash flow-$13.1M+37.5%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$165.47M+88.1%
Enterprise value$137.59M+148%
P/S9.3×+6.5×

Profitability

See full
Gross margin86%-3.0pp
Operating margin-793.6%-1,717pp
Net margin-732.4%-1,503pp

Returns & leverage

See full
Return on equity-91%+656pp
Debt / equity0×0.0×
Current ratio5.1×-1.7×

FAQ

When did Aclaris Therapeutics report Q1 2025 earnings?
Aclaris Therapeutics (ACRS) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Aclaris Therapeutics's Q1 2025 revenue and EPS?
Aclaris Therapeutics reported revenue of $1.5M and eps of $-0.12 for Q1 2025.
Did Aclaris Therapeutics beat estimates in Q1 2025?
Revenue missed the consensus estimate of $3.6M by $2.1M. EPS beat the consensus estimate of $-0.17 by $0.05.
How did Aclaris Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 39.3% from $2.4M a year earlier and eps grew 50.0% from $-0.24.
Where can I find Aclaris Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001558370-25-006851) and the 10-Q periodic report (0001558370-25-006993) directly on SEC EDGAR. The filing index links above go to sec.gov.